These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3587644)

  • 1. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.
    Gancher ST; Nutt JG; Woodward WR
    Neurology; 1987 Jun; 37(6):940-4. PubMed ID: 3587644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients.
    Nutt JG; Woodward WR
    Neurology; 1986 Jun; 36(6):739-44. PubMed ID: 3703280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.
    Nutt JG; Woodward WR; Carter JH; Gancher ST
    Arch Neurol; 1992 Nov; 49(11):1123-30. PubMed ID: 1444877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.
    Rainero I; Gilli M; De Gennaro T; Chiadò I; Delsedime M; Riccio A; Bergamasco B
    Ital J Neurol Sci; 1988 Jun; 9(3):255-9. PubMed ID: 3403218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
    Nutt JG; Woodward WR; Beckner RM; Stone CK; Berggren K; Carter JH; Gancher ST; Hammerstad JP; Gordin A
    Neurology; 1994 May; 44(5):913-9. PubMed ID: 8190296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.
    Deleu D; Ebinger G; Michotte Y
    Eur J Clin Pharmacol; 1991; 41(5):453-8. PubMed ID: 1761073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
    Hardie RJ; Malcolm SL; Lees AJ; Stern GM; Allen JG
    Br J Clin Pharmacol; 1986 Oct; 22(4):429-36. PubMed ID: 3533125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
    Nutt JG
    Ann Neurol; 1987 Oct; 22(4):535-40. PubMed ID: 3324948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease.
    Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
    Neurology; 1993 Feb; 43(2):367-71. PubMed ID: 8437704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
    Chan PL; Nutt JG; Holford NH
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):307-31. PubMed ID: 16320098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.
    Murata M; Mizusawa H; Yamanouchi H; Kanazawa I
    J Neural Transm (Vienna); 1996; 103(10):1177-85. PubMed ID: 9013404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.
    Evans MA; Broe GA; Triggs EJ; Cheung M; Creasey H; Paull PD
    Neurology; 1981 Oct; 31(10):1288-94. PubMed ID: 7202139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.